pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Krazati
drug · small molecule
save

adagrasib

Marketedupdated 6mo ago
by Bristol-Myers Squibb Co🔗 ChEMBL
Approved
community read0 votes

🐶 often sniffed alongside

top 2
  • tagApproval12 co-mentions · 3 sources
  • tagSmall Molecule6 co-mentions · 3 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 1 investigational indication.

indications

investigational
NSCLCBreast CancerColorectal Cancer

targets

GTPase KRas

all catalysts(0)

nothing on the calendar yet

Trials studying adagrasib

  • phase2A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studiesrecruitingn=170
  • phase3Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7recruitingn=626
  • phase3A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)recruitingn=630
  • phase3A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Canceractive not recruitingn=338
  • phase1A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutationterminatedn=6
  • phase1KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumorsrecruitingn=300
  • phase2Genetic Testing in Guiding Treatment for Patients With Brain Metastasesactive not recruitingn=50
  • phase1Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancersterminatedn=1

Patent cliff

source: FDA Orange Book
first barrier falls
Dec 12, 2027
~1.1 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (4)

  • Aug 21, 2043formulationUS 12383503
  • Sep 10, 2041compositionUS 12281113
  • Feb 5, 2041method-of-use (U-3953)US 12336995
  • May 17, 2037compositionUS 10689377

FDA exclusivities (2)

  • Dec 12, 2029ODE-352Orphan Drug (7y)3.1y
  • Dec 12, 2027NCENew Chemical Entity (5y)1.1y

News(9)

  • From RAS rivalries to leaked cancer vaccine readouts, ESMO brought the data drama
    Every ESMO conference is eventful, but the drama kicked into gear earlier than expected this year when the eagerly anticipated phase 3 data for Moderna and Merck & Co.’s cancer vaccine were leaked…
    fiercebiotech · 21d ago
  • ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ data
    At one of the year’s premiere meetings for cancer research, melanoma vaccine data hailed by scientists sparked a share sell-off on Wall Street, while a lung drug received a standing ovation.
    biopharma_dive · 21d ago
  • ESMO: Roche touts ‘convincing’ phase 3 KRAS data after win over rivals
    Roche has shed more light on its investigational KRAS G12C inhibitor’s phase 3 victory over Amgen’s Lumakras and Bristol Myers Squibb’s Krazati.
    fiercebiotech · 24d ago
  • Krazati withdrawal completed; Wegovy trial meets endpoint for kids ages 6 to 12
    Plus news about Structure Therapeutics, Cloverleaf Bio and Windward Bio. FDA finalizes Krazati withdrawal: Regulators officially finalized the drug’s withdrawal in second-line colorectal cancer las…
    endpoints · 2mo ago
  • GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer asset
    GSK is handing over $110 million upfront to Hutchmed in a deal worth up to $1.295 billion to get its hands on a first-in-class oncology candidate.
    fiercebiotech · 2mo ago
  • Bristol Myers details Krazati confirmatory study failure in colorectal cancer
    While Americans geared up for the July 4 holiday, Bristol Myers Squibb laid out how a confirmatory trial for its drug Krazati failed in colorectal cancer. Patients taking Krazati plus another drug,…
    endpoints · 4mo ago
  • Roche KRAS drug succeeds in head-to-head lung cancer study
    The Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell lung cancer.
    biopharma_dive · 4mo ago
  • ‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancer
    Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically tough-to-treat tumor.
    biopharma_dive · 5mo ago
  • Krazati fails confirmatory trial in colorectal cancer, putting approval at risk
    Bristol Myers Squibb’s cancer drug Krazati has failed its confirmatory study in second-line colorectal cancer, a company spokesperson confirmed to Endpoints News. Krazati had received accelerated a…
    endpoints · 6mo ago
brand
Krazati
trade names
Krazati
generic
adagrasib
MOA
GTPase KRas inhibitor
indication
Non-Small Cell Lung Cancer
phase
marketed
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 4h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?